RT Journal Article
SR Electronic
T1 Proteomics screening post pediatric allogeneic hematopoietic stem cell transplantation reveals an association between increased expression of inhibitory receptor FCRL6 on γδ T cells and CMV reactivation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.02.23297952
DO 10.1101/2023.11.02.23297952
A1 Alexandersson, Adam
A1 Venäläinen, Mikko S
A1 Heikkilä, Nelli
A1 Huang, Xiaobo
A1 Taskinen, Mervi
A1 Huttunen, Pasi
A1 Elo, Laura L
A1 Koskenvuo, Minna
A1 Kekäläinen, Eliisa
YR 2023
UL http://medrxiv.org/content/early/2023/11/21/2023.11.02.23297952.abstract
AB Objective To study kinetics and associations between inflammation related proteins in circulation after pediatric allogenic hematopoietic stem cell transplantation (HSCT) to reveal proteomic signatures or individual soluble proteins associated with specific complications post HSCT.Methods We used a proteomics method called Proximity Extension Assay to repeatedly measure 180 different proteins together with clinical variables, cellular immune reconstitution, and blood viral copy numbers in 27 children aged 1-18 years during a two-year follow up after allogenic HSCT. Protein profile analysis was done using unsupervised hierarchical clustering and a regression-based method, while Bonferroni-corrected Mann-Whitney U test was used for time point specific comparison of individual proteins against outcome.Results At 6 months after allogenic HSCT, we could identify a protein profile pattern associated with occurrence of the complications chronic graft-versus-host disease, viral infections, relapse, and death. When protein markers were analyzed separately, the plasma concentration of the inhibitory and cytotoxic T cell surface protein FCRL6 (Fc receptor-like 6) was higher in patients with CMV viremia (log2-fold change 1.5 (p0.00099), 2.5 (p=0.00035) and 2.2 (p=0.045) at time points 6, 12 and 24 months). Flow cytometry confirmed that FCRL6 expression was higher in innate-like γδ T cells, indicating that these cells have a role in controlling CMV reactivation in HSCT recipients.Conclusions The potentially druggable FCRL6 receptor on cytotoxic T cells appears to have a role in controlling CMV viremia post-HSCT. Our results suggest that system level analysis is a useful addition to the studying of single biomarkers in allogeneic HSCT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAA reports funding from Finska Lakaresallskapet and Lastentautien Tutkimussaatio. MSV reports funding from the Academy of Finland (grant number 322123). EK reports funding from Lastentautien tutkimussaatio; University of Helsinki research funds and Helsinki University Hospital Governmental Funding for Research. LLE reports funding from the European Research Council ERC (677943); European Union Horizon 2020 research and innovation programme (955321); Academy of Finland (310561; 314443; 329278; 335434; 335611 and 341342); Sigrid Juselius Foundation; Biocenter Finland and ELIXIR Finland. XH and PH report no competing financial interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Helsinki University Hospital (permit number: HUS/2306/2016) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors